
Opinion|Videos|June 18, 2024
Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
How will the potential approval of ribociclib for early breast cancer change your treatment paradigms?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives
2
Shingles Vaccination Lowers Risk of Heart Disease, Dementia, and Death in Older Adults
3
Gut Microbiota-Derived Molecule May Enhance Immunotherapy Response in Lung Cancer
4
Study Shows Pitavastatin Could Be a Promising Therapy for Triple-Negative Breast Cancer
5
















































































































































































































